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DOI 10.1016/j.neuron.2010.04.008SUMMARY are thought to function as presynaptic cell-adhesion moleculesNeurexins are presynaptic cell-adhesion molecules
that form trans-synaptic complexes with postsyn-
aptic neuroligins. When overexpressed in nonneuro-
nal cells, neurexins induce formation of postsynaptic
specializations in cocultured neurons, suggesting
that neurexins are synaptogenic. However, we find
that when overexpressed in neurons, neurexins do
not increase synapse density, but instead selectively
suppressed GABAergic synaptic transmission with-
out decreasing GABAergic synapse numbers. This
suppression was mediated by all subtypes of neurex-
ins tested, in a cell-autonomous and neuroligin-inde-
pendent manner. Strikingly, addition of recombinant
neurexin to cultured neurons at submicromolar
concentrations induced the same suppression of
GABAergic synaptic transmission as neurexin overex-
pression. Moreover, experiments with native brain
proteins and purified recombinant proteins revealed
that neurexins directly and stoichiometrically bind to
GABAA receptors, suggesting that they decrease
GABAergic synaptic responses by interacting with
GABAA receptors. Our findings suggest that besides
their other well-documented interactions, presyn-
aptic neurexins directly act on postsynaptic GABAA
receptors, which may contribute to regulate the excit-
atory/inhibitory balance in brain.
INTRODUCTION
Neurexins are receptors for the presynaptic neurotoxin a-latro-
toxin (Ushkaryov et al., 1992; Ushkaryov and Su¨dhof, 1993) andby binding to postsynaptic neuroligins and leucine-rich repeat
transmembrane proteins (LRRTMs) (Ichtchenko et al., 1995;
Nguyen and Su¨dhof, 1997; Irie et al., 1997; Scheiffele et al.,
2000; Ko et al., 2009a; de Wit et al., 2009). In vertebrates, neurex-
ins and neuroligins are synthesized throughout the brain in all
excitatory and inhibitory neurons (Ullrich et al., 1995; Ichtchenko
et al., 1995, 1996). Neurexins and neuroligins are evolutionarily
conserved, indicating that they perform a basic synaptic function
(Tabuchi and Su¨dhof, 2002; Li et al., 2007; Zeng et al., 2007; Bis-
was et al., 2008). Moreover, neurexins belong to a larger protein
family that includes neurexin-like proteins such as CASPR/
CNTNAPs in vertebrates (Peles et al., 1997), neurexin-IV in
Drosophila (Baumgartner et al., 1996), and Bam-2 in C. elegans
(Colavita and Tessier-Lavigne, 2003). All of these molecules func-
tion as cell-adhesion and signaling proteins, and contain typical
neurexin domains (laminin-neurexin-sex hormone-binding glob-
ulin [LNS] domains with interspersed epidermal growth factor
[EGF]-like domains), but are otherwise quite different (Missler
et al., 1998a). In addition to neuroligins and LRRTMs, neurexins
bind to dystroglycan (Sugita et al., 2001) and to neurexophilins
(Petrenko et al., 1996; Missler et al., 1998b), but these interac-
tions have not been studied in detail.
Vertebrate genomes contain three neurexin genes, each of
which expresses larger a- and smaller b-neurexins from distinct
promoters (Rowen et al., 2002; Tabuchi and Su¨dhof, 2002).
Furthermore, extensive alternative splicing of the primary tran-
scripts of alla- and b-neurexins additionally diversifies neurexins,
resulting in potentially thousands of evolutionarily conserved iso-
forms that are differentially expressed in brain (Ushkaryov et al.,
1994; Ullrich et al., 1995; Patzke and Ernsberger, 2000; Zeng
et al., 2006; Rissone et al., 2007; Rozic-Kotliroff and Zisapel,
2007). Although affinity of neurexins for neuroligins depends on
their alternative splicing (Ichtchenko et al., 1995, 1996; Boucard
et al., 2005; Chih et al., 2006; Comoletti et al., 2006), the general
significance of neurexin alternative splicing remains unknown.Neuron 66, 403–416, May 13, 2010 ª2010 Elsevier Inc. 403
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Neurexin Regulation of GABAA Receptor FunctionEndogenous neurexins are largely presynaptic, as evidenced
by their role as a-latrotoxin receptors (Ushkaryov et al., 1992; Su-
gita et al., 1999), their immunocytochemical localization in brain
(Ushkaryov et al., 1992), and their accumulation and functional
requirement in presynaptic nerve terminals in artificial synapses
(Chubykin et al., 2005; Ko et al., 2009b). In mice, deletion of a-
neurexins causes a presynaptic phenotype that includes a major
decrease in action-potential-evoked neurotransmitter release,
and a massive impairment in Ca2+-channel function (Missler
et al., 2003; Zhang et al., 2005). In Drosophila, mutation of the
single neurexin gene (which encodes an a-neurexin; Tabuchi
and Su¨dhof, 2002) also causes an ultrastructural and functional
disorganization of neuromuscular junctions (Li et al., 2007).
Consistent with a presynaptic localization and suggestive of
a synaptogenic function, overexpressed neurexins in nonneuro-
nal cells induce formation of postsynaptic specializations in co-
cultured neurons (Graf et al., 2004; Nam and Chen, 2005).
However, neurexins may also have postsynaptic effects because
a-neurexin KO mice display a relative loss of postsynaptic
NMDA-receptor activity (Kattenstroth et al., 2004), and neurexins
may partly localize postsynaptically (Taniguchi et al., 2007).
Viewed together, the existing data thus suggest that neurexins
function as presynaptic cell-adhesion molecules with essential
functions in all organisms tested. However, no clear-cut view
of the exact nature of these functions has emerged. Whereas
the genetic data in mice and flies argue for a role in synapse
assembly and function, but not in synaptogenesis (Missler
et al., 2003; Li et al., 2007), the induction of postsynaptic special-
izations by transfected neurexins indicates a synaptogenic
function (Graf et al., 2004; Nam and Chen, 2005). Because the
effects of neurexin overexpression in neurons have not been
examined, it is unclear whether neurexins generally trigger
formation of postsynaptic specializations. Moreover, a flurry of
recent human genetics studies suggested that changes in the
neurexin-1a gene are associated with autism (Szatmari et al.,
2007; Kim et al., 2008; Yan et al., 2008; Marshall et al., 2008;
Zahir et al., 2008) and/or schizophrenia (Kirov et al., 2008;
Rujescu et al., 2009; Walsh et al., 2008), while changes in the
neurexin-3a gene are linked to addiction (Hishimoto et al., 2007;
Lachman et al., 2007; reviewed in Su¨dhof, 2008). Here, we show
that neurexins unexpectedly interact with GABAA receptors, and
that overexpression of neurexins in neurons is not synaptogenic,
but selectively inhibits GABAergic synaptic responses by a
neuroligin-independent mechanism. These data suggest that
neurexins may organize synapses not only via trans-synaptic
interactions with postsynaptic cell-adhesion molecules, but also
with neurotransmitter receptors.
RESULTS
Neurexin-2b Downregulates GABAergic Synaptic
Transmission
When neuroligins or neurexins are overexpressed in nonneuronal
cells that are cocultured with neurons, neuroligins induce forma-
tion of presynaptic specializations in the cocultured neurons,
while neurexins induce formation of postsynaptic specializations
(Scheiffele et al., 2000; Graf et al., 2004; Chubykin et al., 2005;
Nam and Chen, 2005). Moreover, overexpression of neuroligins404 Neuron 66, 403–416, May 13, 2010 ª2010 Elsevier Inc.in neurons increases synapse numbers (Chih et al., 2004;
Boucard et al., 2005; Zhang et al., 2009). We therefore hypothe-
sized that overexpression of neurexins in neurons should also
increase synapse numbers.
We infected cultured neurons with lentiviruses expressing
enhanced green fluorescent protein (EGFP) alone or together
with neurexin-2b, such that virtually all neurons are infected.
We then measured in these neurons spontaneous miniature
excitatory and inhibitory postsynaptic currents (mEPSCs and
mIPSCs, respectively). Neurexin-2b caused no change in
mEPSCs, but surprisingly induced an 2-fold decrease in
mIPSC frequency, without a significant change in mIPSC ampli-
tude (Figures 1A, 1B, S1A, and S1B). EGFP alone had no effect.
We next recorded evoked synaptic responses (ESPCs and
IPSCs), and detected a similar selective 2-fold decrease in
IPSC amplitude and charge, again without a significant change
in EPSCs (Figures 1C and 1D). This selective impairment in inhib-
itory GABAergic synaptic transmission by neurexin-2bwas inde-
pendent of alternative splicing at splice site 4 (Figures 1E and 1F).
Using immunocytochemistry, we found that neurexin-2b had
no significant effect on the number or size of inhibitory synapses
(Figures 1G and 1H). Protein quantitations showed that neurexin-
2b caused a small but significant decrease in the levels of pre-
and postsynaptic proteins specific for GABAergic synapses,
without changing their mRNA levels (Figures 1I, 1J, and S1C).
Thus, contrary to expectations, increasing neuronal neurexin-
2b expression decreased the function of GABAergic but not
glutamatergic synapses, without altering synapse numbers.
Neurexins Decrease GABAergic Responses
in Transfected Neurons
We next transfected neurons with neurexin-2b or a control
plasmid, such that only a small percentage of neurons express
neurexin-2b, and recorded from the transfected neurons that
were identified via cotransfected cyan fluorescent protein
(CFP). Similar to lentiviral delivery of neurexin-2b, transfection
of neurexin-2b caused a selective >2-fold decrease in mIPSC
frequency (Figures 2A and S2A) and in evoked IPSC amplitude,
without altering EPSCs (Figures 2B–2E). To ensure specificity
of the observed effect, we measured IPSCs in neighboring trans-
fected and nontransfected neurons on the same coverslip
(Figure 2B). Only transfected neurons expressing neurexin-2b
exhibited depressed GABAergic synaptic responses. The neu-
rexin-2b induced decrease in IPSCs was not alleviated when
neurotransmitter release was increased by elevating the extra-
cellular Ca2+ concentration (Figures 2C and 2D). Moreover,
IPSCs induced by hypertonic sucrose (which induces exocytosis
of all readily releasable vesicles) were also significantly
decreased by transfected neurexin-2b (Figure 2F).
Similar to panneuronal lentiviral expression of neurexin-2b,
transfection of neurexin-2b did not significantly change the
density of excitatory or inhibitory synapses (Figures S2B–S2E).
Immunocytochemically, no change in the postsynaptic neuroli-
gin signal was observed, whereas we detected a small but signif-
icant decrease in the synaptic signal for GABA-Aa1 receptors
and GAD65 (Figure 2G), consistent with the decrease in
GABAergic synaptic protein levels after lentiviral expression of
neurexin-2b (Figures 1I and 1J).
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Figure 1. Lentivirally Expressed Neurexin-
2b Decreases GABAergic but Not Glutama-
tergic Synaptic Strength
All data are from cultured hippocampal neurons
infected with lentivirus expressing EGFP only
(control), or coexpressing EGFP with neurexin-2b
lacking an insert in splice site 4 (Nrx-2b), or other
versions of neurexin-2b as specified.
(A and B) Representative traces (left) and summary
graphs of the frequency (center) and amplitudes
(right) of mEPSCs (A) or mIPSCs (B) recorded in
1 mM tetrodotoxin (TTX) and 0.1 mM picrotoxin
(A) or 10 mM CNQX (B) (mEPSCs: control: n =
25 cells/3 cultures; Nrx-2b: n = 26/3; mIPSCs:
control: n = 29/3; Nrx-2b: n = 27/3).
(C and D) Representative traces (left) and summary
graphs of the amplitude (center) and synaptic
charge transfer (right, integrated over 0.2 s) of
action-potential-evoked EPSCs recorded in
0.1 mM picrotoxin (C) or IPSCs recorded in 10 mM
CNQX (D; N-terminally truncated neurexin-1b
[Ct-Nrx-1b] was included as additional negative
control) (EPSCs: control: n = 54/8; Nrx-2b: n =
59/8; IPSCs: control: n = 12/3; Nrx-2b: n = 13/3;
Ct-Nrx-1b: n = 15/3).
(E and F) Representative traces (left) and summary
graphs of the amplitudes (right) of EPSCs (E) and
IPSCs (F) in neurons infected with control lenti-
virus, or lentivirus expressing neurexin-2b without
(SS4) and with an insert in splice site 4 (+SS4),
recorded as described for (C) and (D) (EPSCs:
control, n = 11/2; Nrx-2b +SS4, n = 11/2; Nrx-2b
-SS4, n = 11/2. IPSCs: control, n = 50/8; Nrx-2b
+SS4, n = 51/8; Nrx-2b -SS4, n = 46/8).
(G) Representative images of neurons infected
with control and neurexin-2b expressing lentivi-
ruses stained for MAP2 and the vesicular GABA
transporter vGAT.
(H) Quantitation of synapse area (left) and density
(right) in the experiments described in (G) (control:
n = 29/3; Nrx-2b: n = 40/3).
(I and J) Representative immunoblots (I) and
summary graphs of protein levels (J) measured in
lysates of cultured hippocampal neurons infected
with control or Nrx-2b-expressing lentivirus. Pro-
tein levels were measured by quantitative immuno-
blotting with 125I-labled secondary antibodies and
PhosphorImager detection (n = 3–5 cultures).
For all representative traces and images, scale
bars apply to all panels in a set. All summary graphs
show mean ± SEM; statistical comparisons were
made by Student’s t test (*p < 0.05, **p < 0.01,
***p < 0.001). For additional data, see Figure S1.
Neuron
Neurexin Regulation of GABAA Receptor FunctionTo test whether all neurexins decrease GABAergic synaptic
transmission, we tested neurexin-1b, -1a, -2b, and -3b. All
neurexins similarly impaired IPSCs (Figure 3A; for neurexin-1a,
see Figure 4B). Transfection of C-terminally truncated neu-
rexin-2bDct lacking the cytoplasmic neurexin tail also decreased
IPSCs, whereas deletion of the extracellular sequences of
neurexin-1b abolished suppression of IPSCs, suggesting that
postsynaptically expressed neurexin acts by an extracellular
interaction (Figure 3B).
Does overexpressed neurexin block the maturation of new
synapses, or impair the function of existing synapses? Toexamine this question, we monitored the time course of neu-
rexin-induced suppression of IPSCs. We transfected neurons
with neurexin-2b or control vector at 10 days in vitro (DIV10),
and measured the IPSC amplitudes 24–96 hr after transfection.
Control-transfected neurons exhibited a continuous increase
in IPSC amplitudes after DIV10, consistent with progressive
maturation of synapses. In contrast, neurexin-2b-expressing
neurons displayed no further increase in IPSC amplitudes after
DIV10 (Figure 3C). Thus, neurexin-2b did not impair existing
GABAergic synapses, but prevented the normal developmental
increase in inhibitory synaptic strength. This observation cannotNeuron 66, 403–416, May 13, 2010 ª2010 Elsevier Inc. 405
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Figure 2. Postsynaptic Expression of Neurexin-2b Impairs Inhibitory Synaptic Strength
All data are from cultured hippocampal neurons cotransfected with an EGFP expression plasmid and either an empty vector (control), or a vector encoding neu-
rexin-2b (Nrx-2b).
(A) Representative traces (left) and summary graphs of the mean frequency (center) and amplitudes (right) of mIPSCs recorded in 1 mM TTX and 10 mM CNQX
(control: n = 26/3; Nrx-2b: n = 24/3).
(B) Representative traces (left), mean amplitudes (center), and IPSC ratio (right) of IPSCs recorded from neighboring transfected and nontransfected neurons
(control: n = 11 pairs/3 cultures; Nrx-2b: n = 12 pairs/3 cultures).
(C and D) Representative traces (C) and summary graphs of the amplitudes (D, left) and synaptic charge transfer (D, right) of IPSCs recorded in 1, 2, and 5 mM
extracellular Ca2+ (control: n = 17/3, 17/3 and 20/3 at 1, 2 and 5 mM extracellular Ca2+; Nrx-2b: n = 17/3, 18/3 and 23/3 at 1, 2, and 5 mM Ca2+).
(E) Representative traces (left), mean amplitudes (center), and mean charge transfer (right) of EPSCs recorded from control or neurexin-2b-transfected neurons
in the presence of 10 mM picrotoxin (control: n = 28/4; Nrx-2b: n = 32/4).
(F) Representative traces (left) and mean charge transfer (right; integrated over 60 s) of IPSCs elicited by hypertonic sucrose (0.5 M for 30 s; control: n = 36/8; Nrx-
2b: n = 42/8).
(G) Measurement of synaptic signals for neuroligins and GABA-Aa1 receptors in neurons expressing neurexin-2b. Transfected neurons were stained with a pan-
neuroligin antibody (Song et al., 1999) and synaptotagmin-1 (Syt1), or for GABA-Aa1 receptors and GAD65. Panels show representative images (left) and quan-
titations of the staining intensity per synapse for all four markers (right).
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Neurexin Regulation of GABAA Receptor Functionbe explained by an indirect effect of neurexins on synaptic
activity, because chronic increases or decreases in synaptic
activity (by incubating neuronal cultures with picrotoxin or with
CNQX, APV, tetrodotoxin, or a combination thereof, respec-
tively) caused no change in the suppression of IPSCs by neu-
rexin-2b (Figure S3).
Neurexins Act on GABAergic Responses Independent
of Neuroligins
Neuroligin-2 is localized to inhibitory synapses, is essential for
normal inhibitory synaptic strength in brain, and binds to all neu-
rexins (Graf et al., 2004; Varoqueaux et al., 2004, 2006; Comoletti
et al., 2006; Chubykin et al., 2007). Thus, neurexins may impair
IPSCs by a selective sequestration of neuroligin-2.
To test this hypothesis, we coexpressed neurexin-1b or -1a
with neuroligin-1 or -2 in neurons, with the notion that because
both neuroligins bind to neurexins, they would both similarly
counteract the sequestration of endogenous neuroligin-2 by
overexpressed neurexins. However, coexpression of neuroli-
gin-1 had no effect on the suppression of IPSCs by neurexins.
Neuroligin-2 alone enhanced IPSCs as described (Chubykin
et al., 2007); coexpression of neuroligin-2 with neurexins
canceled out the effects of each separate protein (Figures 4A
and 4B). Moreover, we found that overexpression of neurexin-
2b produced the same suppression of GABAergic responses in
neurons from neuroligin-2 and -3 knockout (KO) mice (Figures
4C and 4D). Note that different from acute slices (Chubykin
et al., 2007), neuroligin-2 KO neurons did not exhibit a decrease
in IPSC amplitude in culture (Figure S4A). Furthermore, we found
that a neurexin mutant (neurexin-2bD137A) that does not bind to
neuroligins (Reissner et al., 2008; see also Figure 7 below) still
effectively decreased IPSCs (Figure 4E). Finally, to explore
whether neurexin binding to dystroglycan (Sugita et al., 2001)
may decrease IPSCs, we examined the effect of dystroglycan
transfection on IPSCs, either alone or in combination of neurex-
ins. Dystroglycan had no effect either on IPSCs when transfected
alone, or on the neurexin-induced suppression of IPSCs
(Figure 4F).
Together, these data show that increasing neurexin expres-
sion does not impair inhibitory synaptic transmission by seques-
tering endogenous neuroligins. Given the primarily presynaptic
localization of neurexins, the question arises whether trans-
fected neurexins decrease inhibitory synaptic strength by a
true postsynaptic action, or act in the postsynaptic neuron only
after reaching synapses at the cell surface, and thus act by
a quasi-presynaptic mechanism. Panneuronal loss-of-function
experiments of neurexins cannot be used to address this ques-
tion because loss of a-neurexins alone already severely impairs
neurotransmitter release, preempting any analysis of a postsyn-
aptic effect (Missler et al., 2003). Thus, we addressed this
question by testing whether a selective postsynaptic shRNA-
dependent knockdown of all neurexins causes a phenotype
opposite to the neurexin overexpression (Figures S4B–S4F),
which would indicate a normally postsynaptic function of neu-For all representative data, scale bars apply to all panels in a set. All summary graph
nonsignificant, *p < 0.05; **p < 0.01, ***p < 0.001. For additional data, see Figure S2rexins in this regard, and whether expression of a neurexin
mutant that is retained in the endoplasmic reticulum (ER) still
suppresses inhibitory synaptic transmission (Figures 4G, 4H,
and S4G–S4I).
We developed shRNAs that efficiently knock down expression
of all a- and b-neurexins (Figure S4B). Expression of these
shRNAs in transfected neurons, however, did not cause a change
in inhibitory synaptic transmission, either in spontaneous or
evoked synaptic responses (Figures S4C–S4F). Next, we ex-
pressed a soluble truncated neurexin-2b mutant that contains
a C-terminal KDEL sequence (Nrx-2bKDEL). Nrx-2bKDEL still binds
to neuroligins, but is retained in the ER, and had no effect on
inhibitory synaptic transmission (Figures 4G, 4H, and S4G–S4I).
Thus, neurexins have to be exported through the secretory
pathway in order to act on GABAergic synapses, and transfected
neurexins likely do not act in the postsynaptic neuron proper, but
at synapses on the surface of the transfected neuron in a manner
simulating a presynaptic action.
Recombinant Neurexin-1b Added to the Medium
Suppresses GABAergic Responses
If neurexins act on inhibitory synapses via an extracellular effect,
recombinant neurexins added to the medium should simulate
this action. To test this hypothesis, we incubated cultured
neurons from DIV10 to DIV14 with a recombinant neurexin
protein composed of the extracellular domains of neurexin-1b
fused to the Fc domain of human immunoglobulin (IgNrx-1b),
using recombinant protein containing only the human immuno-
globulin domain (IgC) as a control. IgNrx-1b specifically
decreased the mIPSC frequency but not the mIPSC amplitude
(Figure 5A), and suppressed evoked IPSCs but not evoked
EPSCs; IgNrx-1b concentrations as low as 0.5 mM were effective
(Figures 5B, S5A, and S5B). Similar to transfected neurexins,
IgNrx-1b caused a significant decrease in the readily releasable
pool at GABAergic synapses (Figure 5C), but produced no
detectable alteration in release probability as monitored with
the paired-pulse ratio (Figure S5C). Moreover, protein measure-
ments revealed that IgNrx-1b only produced a small change in
proteins specific for GABAergic synapses without other major
changes (Figure S5D). Thus, simple addition of extracellular neu-
rexin-1b protein selectively suppresses GABAergic synapse
function.
We next studied the time course of IgNrx-1b action on IPSCs.
We either added 1 mM IgNrx-1b at defined times between DIV10
and DIV14, and measured IPSCs at DIV14 (Figure 5D), or we
added IgNrx-1b at DIV10, and measured IPSCs 24–96 hr after-
wards (Figure 5E). In both types of experiments, addition of neu-
rexin-1b prevented the normal developmental increase in IPSC
size, without a significant effect on IPSCs already present at
the time at which IgNrx-1b was added. These results, which
agree with those obtained with transfected neurons (Figure 3C),
indicate that neurexins do not inhibit existing GABAergic syn-
apses in neurons, but prevent increases of GABAergic synaptic
strength during the culture period.s show means ± SEMs; statistical comparisons by Student’s t test yielded: n.s. =
.
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Figure 3. Extracellular Sequences of Neurexins Mediate Decrease
of IPSCs
Different neurexins were examined in transfected cultured hippocampal
neurons as described for Figure 2.
(A) Representative traces (top) and mean amplitudes (bottom) of EPSCs and
IPSCs recorded from neurons transfected with control vector or vectors
encoding neurexin-1b (Nrx-1b), -2b (Nrx-2b), or -3b (Nrx-3b; EPSCs: control,
n = 30/4; Nrx-1b, n = 31/4; Nrx-2b, n = 28/4; Nrx-3b, n = 29/4. IPSCs: control,
n = 42/4; Nrx-1b, n = 23/3; Nrx-2b, n = 48/4; Nrx-3b, n = 21/3).
(B) Representative traces (left) and mean amplitudes of IPSCs (right) recorded
from neurons transfected with control vector or vectors expressing wild-type
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Do neurexins interact with components of GABAergic synapses?
To explore this possibility, we immobilized Ig-neurexin and
Ig-control proteins, and performed affinity chromatography
experiments with brain proteins solubilized in Triton X-100.
Immunoblotting of bound proteins with a series of antibodies
revealed specific binding of neuroligin-1 (as expected) and of
GABAA receptors (both the a1 and b2/3 subunits), but not of
AMPA- or of NMDA-type glutamate receptors (Figures 6A, 6B,
and S6A–S6C). Measurements of bound proteins relative to the
flow-through showed that the GABAAa1 receptor was retained
quantitatively, with approximately half the efficiency of neuroli-
gin-1 (Figure 6B). In contrast to neuroligins, binding of
GABAAa1receptor toneurexin wasCa
2+ independent (Figure6B),
and a mutation in the neurexin Ca2+-binding sequence that
blocks neuroligin-1 binding had no effect on GABAAa1-receptor
binding (Figure 6A). These observations were fully confirmed
using recombinant proteins expressed in transfected HEK293
cells (Figures S6D–S6G), suggesting that neurexins directly
bind to GABAAa1 receptors in a Ca
2+-independent manner.
Are endogenous GABAAa1-receptor/neurexin complexes
present in brain? We examined this question by affinity-purifying
neurexins from brain homogenates with an immobilized gluta-
thione S-transferase (GST) fusion protein containing the CASK
PDZ-domain that avidly binds to the C-terminal cytoplasmic
sequence of neurexins (Hata et al., 1996). GST-CASK captured
both GABAAa1 receptor and neuroligin-1 (Figures 6C and 6D).
Quantitations of bound proteins suggested that similar amounts
of the GABAAa1 receptor and neuroligin-1 were bound by the
CASK PDZ-domain (Figure 6D). This binding was not due to
a direct interaction of the GABAAa1 receptor with GST-CASK
because GST-CASK could only affinity-purify the GABAAa1
receptor from transfected HEK293 cells when neurexin-1b was
coexpressed with the receptor (Figure S6H), demonstrating that
GST-CASK pulls down a neurexin/ GABAAa1-receptor complex.
Direct Extracellular Interaction of Neurexins
and GABAAa1 Receptors
The robust effects of neurexin on GABAergic synaptic transmis-
sion (Figures 1–5) could only be accounted for by their interaction
if their extracellular domains bound to each other. Thus, we
produced a recombinant GST-fusion protein of the extracellular
domain of GABAAa1 receptors, and tested its binding to purified
Ig-neurexin. We observed specific binding when either neurexinneurexin-2b (Nrx-2b), C-terminally truncated neurexin-2b (Nrx-2bDCt) com-
posed of its extracellular sequences and transmembrane region with (+) and
without () an insert in splice site 4, or N-terminally truncated neurexin-1b
(Ct-Nrx-1b) composed of only its transmembrane region and cytoplasmic
tail (control: n = 32/5; Nrx-2b: n = 52/5; Nrx-2bDCt without SS4: n = 32/5;
Nrx-2bDCt with SS4: n = 24/4; Ct-Nrx-1b: n = 42/3).
(C) Representative traces (left) and mean amplitudes (right) of IPSCs recorded
from neurons transfected with control or neurexin-2b expressing vectors on
DIV10, and analyzed at the indicated times after transfection (for all times
tested: control, n = 5/3, Nrx-2b, n = 15/3).
For all representative traces, scale bars apply to all traces in a set. All summary
graphs show mean ± SEM; statistical comparisons by Student’s t test yielded:
n.s. = nonsignificant, *p < 0.05; **p < 0.01, ***p < 0.001. For additional data,
see Figure S3.
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Figure 4. Neurexins Impair IPSCs Independent of Neuroligins
Hippocampal neurons transfected with the indicated combinations of expres-
sion vectors were analyzed as described for Figure 2.
(A) Representative traces (left) and mean amplitudes (right) of IPSCs recorded
from neurons transfected with control vector, or vectors expressing only
neurexin-1b (Nrx-1b), only neuroligin-2 (NL2), neurexin-1b together with neuro-
ligin-2 (Nrx-1b + NL2), or neurexin-1b with neuroligin-1 (Nrx-1b + NL1; control:
n = 42/5; Nrx-1b: n = 55/5; Nrx-1b + NL-1: n = 26/4; Nrx-1b + NL-2: n = 25/4;
NL-2: n = 9/1).
(B) Representative traces (left) and mean amplitudes (right) of IPSCs recorded
from neurons transfected with control vector, or vectors expressing only
neurexin-1a (Nrx-1a), or together with neuroligin-2 (Nrx-1a + NL2), or only
neuroligin-1 (Nrx-1a + NL1; control: n = 48/5; Nrx-1a: n = 38/5; Nrx-1a + NL-1:
n = 19/3; Nrx-1a + NL-2: n = 16/3).
(C and D) Representative traces (left) and mean amplitudes (right) of IPSCs
recorded from neurons cultured from neuroligin-2 KO (C) or neuroligin-3 KO
mice (D), and transfected with control vector or neurexin-2b (Nrx-2b; C,
control: n = 20/3; Nrx-2b: n = 19/3; D, n = 9 pairs of neighboring nontransfected
and transfected neurons/3 cultures).
(E) Representative traces (left) and mean amplitudes (right) of IPSCs recorded
from neighboring nontransfected and transfected neurons expressing mutant
neurexin-2b (Nrx-2bD137A) in which a point mutation abolishes Ca2+- and
neuroligin-binding to the neurexin-2b LNS-domain (control: n = 15 pairs/3
cultures).
(F) Mean amplitudes of IPSCs recorded from neurons transfected with control
vector, or vectors expressing neurexin-2b alone (Nrx-2b), neurexin-2b
together with dystroglycan (Nrx-2b + DG), or dystroglycan alone (DG; control:
n = 16/3; Nrx-2b: n = 11/3; Nrx-2b + DG: n = 16/3; DG: n = 12/2).
(G and H) Truncated neurexin-2bwith a C-terminal KDEL sequence is retained
in the ER (G) and unable to decrease IPSCs (H). Panel (G) depicts representa-
tive images of neurons demonstrating that neurexin-2bKDEL is retained in the
ER (Nrx-2bKDEL; visualized via a myc-epitope; top); colabeling for synapsin in
the merged image reveals that the neuron nevertheless forms abundant
synapses (Merged; bottom). Panel (H) (left, representative traces; right,
summary graphs) shows that an ER-retained neurexin-2b mutant that still
binds neuroligin (Figure S4) has no effect on IPSC amplitudes (Nrx-2bKDEL
transfection; control: n = 14/3; Nrx-2bKDEL: n = 13/3; Nrx-2b transfection;
control: n = 8/3; Nrx-2b: n = 8/3).
For all representative traces, scale bars apply to all traces in a set. Summary
graphs show mean ± SEM; statistical comparisons by Student’s t test yielded:
*p < 0.05; **p < 0.01. For additional data, including postsynaptic knockdowns
of neurexins, see Figure S4.
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Neurexin Regulation of GABAA Receptor Functionor the GABAAa1 receptor was pulled down (Figures 7A and 7B).
We next tested whether the GABAAa1 receptor and neuroligin-1
could bind to neurexins simultaneously. Using recombinant
proteins, we found that indeed, immobilized GABAAa1 receptor
captured not only neurexin-2b, but also neuroligin-1, demon-
strating a tripartite interaction (Figure 7C). Finally, we examined
the affinity of the neurexin-GABAAa1 receptor interaction, using
purified recombinantproteins that were not fused toGST or immu-
noglobin (Ig) (Figure 7D). Using surface plasmon resonance
measurements, we found a tight, specific, and saturable interac-
tion between these two proteins with a micromolar affinity, con-
firming a direct binding reaction (Figures 7E and 7F).
Neurexins Inhibit GABAAa1-Receptor Currents
in Transfected HEK293 Cells
Does the interaction of neurexins with GABAA receptors directly
decrease GABAergic currents? To test this question, we trans-
fected neurexin-2b into nonneuronal HEK293 cells that stably
express GABAA receptors on their surface (Wong et al., 1994).Neuron 66, 403–416, May 13, 2010 ª2010 Elsevier Inc. 409
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Figure 5. Recombinant Neurexin-1b in Medium Inhibits IPSCs
All data are from cultured hippocampal neurons incubated with purified control
Ig-fusion protein (IgC) or neurexin-1b Ig-fusion protein containing the extracel-
lular domains of neurexin-1b (IgNrx-1b). Except where noted, neurons were
treated for 96 hr at 37C with 1 mM protein.
(A) Representative traces (left) and summary graphs of the frequency (center)
and amplitudes (right) of mIPSCs monitored in 1 mM TTX and 10 mM CNQX
(IgC: n = 19/3; IgNrx-1b: n = 19/3).
(B) Representative traces (left) and mean amplitudes (right) of evoked IPSCs
recorded from neurons incubated with the indicated concentrations of
IgNrx-1b (control: n = 17/3; 1 mM: n = 12/3; 500 nM: n = 13/3; 100 nM: n = 7/3;
50 nM: n = 7/3).
(C) Representative traces (left) and mean charge transfer (right) of IPSCs eli-
cited by hypertonic sucrose (0.5 M for 30 s; IgC: n = 14/3; IgNrx-1b: n = 15/3).
(D) Representative traces (left) and mean amplitudes (right) of evoked IPSCs
recorded from neurons treated with IgC or IgNrx-1b for the indicated times,
with all incubations ending at DIV14 (24 hr: control, n = 19/3, IgNrx-1b:
n = 14/3; 48 hr: control, n = 14/3, IgNrx-1b: n = 15/3; 72 hr: control, n = 19/3,
IgNrx-1b: n = 19/3; 96 hr: control, n = 14/3, IgNrx-1b: n = 15/3).
(E) Representative traces (left) and mean amplitudes (right) of evoked IPSCs
recorded from neurons treated with IgC or IgNrx-1b for the indicated times
after the incubations were started at DIV10 (24 hr: control, n = 24/4, IgNrx-1b:
n = 26/4; 48 hr: control, n = 18/3, IgNrx-1b: n = 18/3; 72 hr: control, n = 18/3,
IgNrx-1b: n = 22/3; 96 hr: control, n = 18/3, IgNrx-1b: n = 18/3).
For all representative traces, scale bars apply to all traces in a set. All summary
graphs show means ± SEMs; statistical comparisons by Student’s t test
yielded: n.s. = nonsignificant, *p < 0.05; **p < 0.01, ***p < 0.001. For additional
data, see Figure S5.
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HEK293 cells (Figure 8A). Titration of the GABA-induced currents
with different GABA concentrations revealed no change in the
kinetics or dose-response curve, but a general suppression of
the response (Figures 8B and S8). Moreover, incubation of
HEK293 cells expressing GABAA receptors for 48 hr with purified
neurexin protein (IgNrx-2b; 1 mM) also suppressed GABA
currents (Figure 8C). Finally, transfected neurexin-2b decreased
the levels of cellular GABAA-receptor protein (Figure 8D). Thus,
neurexins appear to act directly on GABAA receptors.
DISCUSSION
Here we show that neurexins directly bind to the extracellular
domains of GABAA receptors, and specifically inhibit postsyn-
aptic GABAA receptors by a neuroligin-independent mechanism.
We made six principal observations.
First, neurexins directly interact with GABAAa1 receptors, as
shown by binding of recombinant IgNrx-2b to endogenous
GABAAa1 receptors in brain and to transfected GABAAa1 recep-
tors in HEK293 cells; coimmunoprecipitation of neurexin-1bwith
GABAAa1 receptors from transfected HEK293 cells; pulldown of
endogenous brain neurexin/GABAAa1-receptor complexes and
of recombinant neurexin/GABAAa1-receptor complexes with
the CASK PDZ-domain; and measurements of the direct interac-
tion of the purified extracellular domains of neurexin and GABAA
a1 receptors (Figures 6, 7, S6, and S7).
Second, increasing neurexin expression decreases
GABAergic but not glutamatergic synaptic transmission. This
conclusion is based on lentiviral overexpression of neurexins
(Figure 1), transfection of neurexins (Figures 2 and 3), and addi-
tion of recombinant neurexin to the medium (Figure 5). Neurexins
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Figure 6. Neurexins Form a Complex with GABAA
Receptors
All data shown are from affinity chromatography experi-
ments using immobilized Ig- or GST-fusion proteins and
Triton X-100 solubilized rat brain proteins. All summary
graphs show mean ± SEM. For additional raw data and
controls, see Figure S6.
(A) Affinity purification of GABAA receptors on neurexin-2b.
Immobilized IgC or Ig-fusion proteins of the extracellular
sequences of wild-type neurexin-2b (IgNrx-2b) or of
neurexin-2b with a Ca2+-binding site point mutation that
blocks neuroligin-binding (IgNrx-2bD137A) were used as
affinity matrices for rat brain proteins solubilized in Triton
X-100. Bound proteins were analyzed by immunoblotting
for GABAAa1- and GABAAb2/3 receptors and neuroligin-1.
(B) Quantitative, Ca2+-independent binding of GABAAa1
receptor to IgNrx-2b. Solubilized rat brain proteins were
bound to IgNrx-2b or IgC in the presence of 2.5 mM
Ca2+, or of 0 mM Ca2+ plus 5 mM EDTA. Bound proteins
were analyzed by immunoblotting for GABAAa1 receptor
and neuroligin-1 (NL1) with ECL detection (top), and addi-
tionally quantified for the Ca2+-containing experiments
with 125I-labeled secondary antibodies and PhosphorIm-
ager detection (bottom; mean ± SEM, n = 8).
(C) Affinity chromatography of brain proteins on immobi-
lized GST-CASK containing the CASK PDZ-domain
(GST-CASK), or on GST alone. Bound proteins were
analyzed by immunoblotting for GABAAa1 receptor, neu-
roligin-1 (NL1), GluR1, and NMDA receptor (NMDA-R).
(D) Quantitation of the binding of endogenous brain
GABAAa1 receptor and neuroligin-1 (NL1) to immobilized
GST-CASKorGST.Bound proteinswereanalyzedby immu-
noblotting with 125I-labeled secondary antibodies and Phos-
phorImager detection; top panels show a representative
blot, and bottom panels summary graphs (mean ± SEM;
n = 6). For additional raw data and controls, see Figure S6.
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Neurexin Regulation of GABAA Receptor Functionhave a large effect (>2-fold decrease in IPSCs in most assays)
that is specific (no changes in EPSCs, no decreases in synapse
numbers or major changes in neuronal protein composition;
Figures 1–5 and S1–S5). Possibly most unexpected is the
potency of recombinant neurexin that specifically suppressed
IPSCs at only 0.5 mM (Figure 5). All neurexins tested had a similar
effect that was independent of alternative splicing at site #4
(Figures 1–4).
Third, neurexins act via an extracellular mechanism on the
neuronal surface. This was shown by the effectiveness of re-
combinant neurexin added to the culture medium (Figure 5),
and of overexpressed neurexin-2bDCt, which lacks a cytoplasmic
tail (Figure 3). In contrast, Ct-neurexin-1b, composed of only the
common neurexin cytoplasmic tail and transmembrane region,
was inactive (Figure 3). Moreover, a neurexin-2b mutant that isNeuron 66retained in the ER is inactive, and postsynaptic
knockdown of neurexins has no effect (Figures
4 and S4).
Fourth, neurexins inhibit GABAergic
responses independent of neuroligins. Cotrans-
fection of neurexins with neuroligin-1 or neuroli-
gin-2 did not ablate the inhibitory effect of neu-
rexins on GABAergic synaptic transmission
(Figures 4A and 4B); neurexin-2b still inhibitedGABAergic transmission in KO neurons lacking neuroligin-2,
the only neuroligin specifically involved in inhibitory synaptic
transmission (Chubykin et al., 2007), or neuroligin-3 (Figures
4C and 4D); recombinant neurexin added to cultured neurons
had the same effect as transfected neurexins (Figure 5), which
would not be expected if the overexpressed neurexins seques-
tered neuroligins in the neurons; a neurexin mutant that does
not bind to neuroligins still bound to GABAA receptors, and still
inhibited GABAergic synaptic transmission (Figures 4E and
6A); and a neurexin-2b mutant that is retained in the ER of
neurons where it still binds to neuroligins did not decrease inhib-
itory synaptic strength (Figure 4). Note that the experiments with
the various splice variants of neurexins and their mutants also
rule out a participation of the recently discovered interaction of
neurexins with LRRTMs (Ko et al., 2009b; de Wit et al., 2009)., 403–416, May 13, 2010 ª2010 Elsevier Inc. 411
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Figure 7. Neurexins Directly Bind to GABAAa1 Receptors
All data shown analyze binding of purified recombinant proteins.
(A and B) Binding of purified GST or a GST-fusion protein of the N-terminal domain of human GABAAa1 receptor to Ig-control (IgC) or Ig-neurexin-2b fusion
proteins (IgNrx-2b), analyzed either by immobilizing the GST-fusion proteins and measuring binding of IgNrx-2b (A), or immobilizing the Ig-fusion proteins
and measuring binding of GST-GABAAa1 (B). Binding was visualized by immunoblotting as indicated.
(C) Binding of recombinant flag-tagged neuroligin-1 (NL1) to immobilized GST-GABAAa1 receptors by forming a tripartite complex with neurexin-2b. Immobilized
GST or the GST-GABAAa1 fusion protein were incubated with both neurexin-2b and neuroligin-1, and bound proteins were analyzed by immunoblotting for
neurexin-2b (left) or neuroligin-1 (right).
(D) SDS gels of purified proteins used for binding affinity measurements (left: silver-stained gel of the purified recombinant GABAAa1-receptor N-terminal domain;
right: Coomassie-stained gel of the purified neurexin-1b LNS-domain).
(E) Surface-plasmon resonance sensorgrams showing the binding of neurexin-1b to the extracellular N-terminal domain of the GABAAa1 receptor. Each line
corresponds to the indicated concentration of neurexin-1 b injected onto the immobilized GABAAa1-receptor surface. The sensorgrams demonstrate a concen-
tration-dependent association as expected for a bimolecular association.
(F) Surface-plasmon resonance quantitation of the binding of neurexin-1b to the N-terminal domain of the GABAAa1 receptor. The maximum steady-state binding of
neurexin-1b to theGABAAa1 receptor is plotted as a function of theneurexin-1bconcentration. Dissociation constants were calculated by fitting the curve to a single-
site binding model. Each data point was measured twice, and both measurements are shown on the figure, but overlap with each other. The experiment was
repeated with higher GABAAa1-receptor immobilization on the chip surface, and similar affinities were obtained (data not shown). For additional data, see Figure S7.
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receptors on the cell surface. This conclusion is inherent to the
findings we made in neurons after addition of recombinant
neurexin to the medium (Figure 5) and after transfection of
various neurexin mutants (Figures 2–4), and further amplified
by the finding that transfection of neurexin-2b into GABAA-
receptor-expressing HEK293 cells or addition of IgNrx-2b to
such cells suppressed GABA-induced currents in these non-
neuronal cells (Figure 8).
Sixth, finally, an excess of neurexins does not impair the func-
tions of existing GABAergic sites—receptors and/or synapses—
but prevents the developmental increase of GABAergic synaptic
transmission in cultured neurons. Both for neurexin-transfected
neurons and for untransfected neurons treated with recombi-
nant neurexin, the neurexin ‘‘froze’’ the neuron in the state it412 Neuron 66, 403–416, May 13, 2010 ª2010 Elsevier Inc.was at the point at which the treatment was started (Figures 3
and 5).
Relation to Previous Studies
Our study appears to contradict nearly all previously published
reports on neurexins, including many from our own laboratory.
As described below, however, some of these contradictions
may be more apparent than real.
We observed that excess neurexins selectively decrease
inhibitory synapses, instead of promoting formation of excitatory
synapses as suggested in studies using cocultures of neurons
with transfected nonneuronal cells (Graf et al., 2004; Nam and
Chen, 2005). However, the lack of an effect of neurexins on
synapse formation is consistent with the finding that deletion of
a-neurexins does not decrease the number of excitatory
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Figure 8. Neurexin-2b Impairs GABAAa1 Receptor Function in
Transfected HEK293 Cells
(A) Representative traces (left) and peak amplitudes (right) of currents induced
by application of 0.2 mM GABA to HEK293 cells stably expressing GABAA
receptors (a1b2g2, CRL-2029 from ATCC), and transfected with pCMV5
(control) or vector expressing neurexin-2b (control: n = 18/3; Nrx-2b: n = 18/3).
(B) Plot of the current amplitude induced as described in A. as a function of the
GABA concentration (control: n = 19/4; Nrx-2b: n = 17/4). For a scaled plot to
document a lack of change in apparent GABA-affinity, see Figure S12.
(C) Representative traces (left) and peak amplitudes (right) of currents induced
by application of 0.2 mM GABA to HEK293 cells stably expressing GABAA
receptors that had been incubated for 48 hr with 1 mM control IgC or IgNrx-2b
(control: n = 15/3; IgNrx-2b: n = 16/3).
(D) Quantitation of the levels of GABAAa1 receptor in HEK293 cells that stably
express GABAA receptors, and were transfected with either an empty vector
(control), or a vector encoding neurexin-2b (Nrx-2b) (n = 13 independent
cultures).
For all representative traces, scale bars apply to all traces in a set. All summary
graphs show mean ± SEM; statistical comparisons by Student’s t test yielded
*p < 0.05; **p < 0.01, ***p < 0.001. For additional data, see Figure S8.
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Neurexin Regulation of GABAA Receptor Functionsynapses, and only moderately decreases the number of inhibi-
tory synapses (Missler et al., 2003).
Moreover, we detected an apparently postsynaptic effect of
neurexins, whereas neurexins are thought to function primarily
presynaptically. However, our study shows that postsynaptically
expressed neurexins act in the postsynaptic neuron only after
transport to the cell surface, and thus may in fact mimic a presyn-
aptic effect.
Furthermore, we propose that the observed effect of neurexins
is independent of neuroligins, whereas most processes con-
nected to neurexins can be accounted for by their binding to neu-
roligins. Indeed, because neurexins can be observed postsynap-
tically, they were speculated to be postsynaptic regulators of
neuroligins (Taniguchi et al., 2007). However, there is no reason
why neurexins should not bind to other proteins besides neuroli-
gins (e.g., see Ko et al., 2009a; de Wit et al., 2009), and neuroligins
also have neurexin-independent functions (Ko et al., 2009b).
Finally, our current results differ from those obtained with
a-neurexin KO mice (Missler et al., 2003; Kattenstroth et al.,
2004; Zhang et al., 2005). Here, we observed a selective effect
of neurexins on inhibitory synapses (i.e., it is not simple synapse
damage) that is mediated by an extracellular cell-surface interac-
tion of neurexins with postsynaptic neurons. In contrast, in the KO
studies we foundanessential function ofa-neurexins inorganizing
neurotransmitter release from all presynaptic nerve terminals.
However, a specific change in inhibitory synaptic transmission
would have been unobservable in a-neurexin KO mice (Missler
et al., 2003) because these mice exhibit an overwhelming impair-
ment in neurotransmitter release, which would have occluded
a separate facilitation of inhibitory synapses. Moreover, the
continued expression of b-neurexins in these mice may have pre-
vented manifestation of an inhibitory synapse phenotype. Thus,
despite their differences, it seems likely that the two approaches
revealed distinct parts of the overall picture of neurexin function.Physiological Significance
Our data suggest that neurexins decrease GABAergic synaptic
transmission by direct binding to GABAA receptors on the cell
surface at the synapse, and that neurexins act by impeding theNeuron 66, 403–416, May 13, 2010 ª2010 Elsevier Inc. 413
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formation. Thus, the effects of excess neurexins observed in
our experiments may reflect a function of neurexins in regulating
GABAergic synapse maturation. We propose that this newly
observed activity is one facet of multiple actions of neurexins
at synapses, and that presynaptic neurexins likely constitute
master regulators of synapse maturation (or validation) via
trans-synaptic interactions with an array of postsynaptic targets,
which are only now slowly being discovered, as exemplified by
the identification of LRRTMs as novel neurexin ligands (Ko
et al., 2009a; de Wit et al., 2009). Teasing apart the physiological
importance of the various interactions will require definition of
neurexin mutations that specifically and selectively impair one
interaction without affecting others, because the example of
the a-neurexin KO mice has already demonstrated that global
ablation of neurexin expression is too blunt an instrument in
order to define the full range of neurexin functions. However,
the present observations uncovering a very robust action of neu-
rexins on postsynaptic GABAA receptors extend and expand the
emerging concept that neurexins function not in the initial estab-
lishment of synapses, but in shaping their properties, in their
maturation. A key observation in this regard is the developmental
effect of neurexins in the assays described here, which clearly
shows that once synapses are formed, they are immune from
the effect of overexpressed neurexins. Because synapses are
likely continuously formed throughout adult life, this develop-
mental action naturally continues beyond the actual develop-
ment of the organism, and corroborates the notion of neurexins
as key regulators of synaptic properties.
We propose that the effect of neurexins on postsynaptic
GABAA receptors observed here is likely trans-synaptic.
However, independent of whether the interaction of neurexins
with GABAA receptors is postsynaptic or trans-synaptic, our
findings may shed light on the role of neurexins in cognitive
diseases such as autism, addiction, and schizophrenia (Szatmari
et al., 2007; Kim et al., 2008; Yan et al., 2008; Marshall et al.,
2008; Zahir et al., 2008; Kirov et al., 2008; Rujescu et al., 2009;
Walsh et al., 2008; Hishimoto et al., 2007; Lachman et al.,
2007; reviewed in Su¨dhof, 2008). In these disorders, changes
in inhibitory synaptic transmission are thought to play a major
role. Specifically, alterations in the levels of GABA and GABA
receptors (including GABAAa1) in autistic patients, and muta-
tions in genes expressing GABA receptor subunits (Collins
et al., 2006; Fatemi et al., 2009) suggest that the GABAergic
system may be centrally involved in autism. Additionally, exten-
sive studies have indicated that mutations in GABAAa1-receptor
genes are associated with schizophrenia (Petryshen et al., 2005).
In view of the fact that deletions of neurexin-1 a are also associ-
ated with autism and schizophrenia (Szatmari et al., 2007; Kim
et al., 2008; Yan et al., 2008; Marshall et al., 2008; Zahir et al.,
2008; Kirov et al., 2008; Rujescu et al., 2009; Walsh et al.,
2008; Hishimoto et al., 2007; Lachman et al., 2007), and that
neurexin-1a KO mice exhibit traits resembling schizophrenia
(Etherton et al., 2009), our observation that neurexins physically
and functionally interact with GABAA receptors raises the tanta-
lizing possibility that alterations in GABAergic synaptic transmis-
sion may contribute to a convergent mechanism for increasing
the risk of autism and schizophrenia.414 Neuron 66, 403–416, May 13, 2010 ª2010 Elsevier Inc.EXPERIMENTAL PROCEDURES
Construction of Expression Vectors
Various vectors were produced using standard molecular biology procedures
(see Table S4 and Supplemental Experimental Procedures). The vector encod-
ing YFP-tagged GABAAa1-receptor was a gift from Dr. Robert Macdonald
(Gallagher et al., 2005).
Neuronal Cultures and Ca2+-Phosphate Transfections
Primary hippocampal neurons were cultured on poly-D-lysine-coated glass
coverslips from 1- to 3-day-old mice (Maximov et al., 2007), and transfected
with various vectors at DIV10 using a Ca2+-phosphate transfection method
(see Supplemental Experimental Procedures). As visualized by the cotrans-
fected CFP, 1%–2% of neurons were typically transfected.
Lentiviral Infection
Lentiviruses were produced by transfecting HEK293 cells (CRL-11268, ATCC)
with the respective pFUGW vectors and two helper plasmids (pVSVg and
pCMVD8.9). Viruses were harvested 48 hr after transfection by collecting
the medium from transfected cells. Neurons were infected with 0.2–0.5 ml
conditioned HEK293 cell medium for each 24 well of high-density neurons at
DIV1–2, and the medium was exchanged to normal growth medium at DIV4,
then kept until DIV13-DIV15 for biochemical and electrophysiological anal-
yses. For all experiments, expression of exogenous proteins in neurons was
confirmed by immunoblotting and GFP fluorescence.
Immunofluorescence analyses were performed as described previously
(Chubykin et al., 2007), and analyzed blindly using the NIH ImageJ program.
Electrophysiological recordings were performed as described elsewhere
(Maximov and Su¨dhof, 2005; Maximov et al., 2007) using a Multiclamp 700A
amplifier (Molecular Devices).
Synaptic responses were evoked by 0.5 ms current injections (90100 mA)
with an Isolated Pulse Stimulator (Model 2000, A-M Systems, Inc.) using a
concentric bipolar electrode (FHC, CBAEC75) that was placed at a 100 mm
distance from the patched neuron. The RRP was measured by perfusion of
hypertonic sucrose (0.5 M) into the bath solution at 2 ml/min. Series resistance
was compensated to 60%–70%, and recordings with series resistances
of >20 MU were rejected. Data were analyzed using Clampfit 9.02 (Molecular
Devices) and Igor 4.0 (Wavemetics).
Recombinant Proteins
Ig-neurexins were produced in transfected COS cells and bacterial recombi-
nant proteins were generated and purified as described previously (Boucard
et al., 2005; Hata et al., 1996; Arac¸ et al., 2007; see Supplemental Experimental
Procedures).
Protein Interaction Measurements Using Affinity Chromatography,
Pulldowns, and Surface Plasmon Resonance Experiments
Affinity-chromatography experiments were performed with proteins solubi-
lized in Triton X-100 from rat brain or from transfected HEK293 cells (Ichtch-
enko et al., 1995; see Supplemental Experimental Procedures). Surface plas-
mon resonance measurements were performed with the recombinant
extracellular N-terminal regions of the neurexin-1b (Arac¸ et al., 2007) and of
the rat GABAAa1 receptor (residues 28-251) essentially as described else-
where (Arac¸ et al., 2007; Garboczi et al., 1996; see Supplemental Experimental
Procedures).
Miscellaneous
SDS-PAGE and immunoblotting experiments, including quantitation with
125I-labeled secondary antibodies followed by PhosphorImager detection
(Molecular Dynamics) were performed as described elsewhere (Tabuchi
et al., 2007). Most antibodies employed were previously characterized (Ichtch-
enko et al., 1995; Song et al., 1999; Sugita et al., 2001; Ushkaryov et al., 1992)
or purchased (GABAAa1 antibodies from Santa Cruz [sc-7348, dilution 1:200],
or Alomone Labs [AGA-001, 1:200]). HEK293 cells stably expressing GABAA
receptors were obtained from the ATCC (CRL-2029). All HEK293 and COS
cell transfections were performed using FUGENE 6 (Roche Applied Science).
Neuron
Neurexin Regulation of GABAA Receptor FunctionStatistical Analyses
All data were generated in at least three independent experiments, and are
shown as mean and standard error of the mean (±SEM). Statistical significance
was determined by the Student’s t test or the Kolmogorov-Smirnov test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.neuron.2010.04.008.
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